Detalhe da pesquisa
1.
Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study.
Headache
; 63(7): 908-916, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37314065
2.
Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
Cephalalgia
; 42(8): 769-780, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35331009
3.
Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction.
Eur J Neurol
; 29(7): 2129-2137, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35302681
4.
Burden of migraine in Brazil: A cross-sectional real-world study.
Headache
; 62(10): 1302-1311, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36426738
5.
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States.
J Headache Pain
; 23(1): 54, 2022 May 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35508970
6.
Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
J Headache Pain
; 23(1): 112, 2022 Aug 29.
Artigo
Inglês
| MEDLINE | ID: mdl-36038833
7.
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
J Headache Pain
; 23(1): 56, 2022 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-35578182
8.
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study.
J Headache Pain
; 23(1): 47, 2022 Apr 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35410121
9.
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
Cephalalgia
; 41(10): 1075-1088, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33990144
10.
Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Headache
; 61(6): 916-926, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34115380
11.
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
Headache
; 61(9): 1376-1386, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34374086
12.
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.
Headache
; 61(4): 662-672, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33891348
13.
Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
J Headache Pain
; 22(1): 2, 2021 Jan 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33413075
14.
Immunogenicity of biologic therapies for migraine: a review of current evidence.
J Headache Pain
; 22(1): 3, 2021 Jan 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33413094
15.
Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial.
J Headache Pain
; 22(1): 26, 2021 Apr 16.
Artigo
Inglês
| MEDLINE | ID: mdl-33863272
16.
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
J Headache Pain
; 22(1): 68, 2021 Jul 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34246226
17.
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States.
J Headache Pain
; 22(1): 156, 2021 Dec 20.
Artigo
Inglês
| MEDLINE | ID: mdl-34930112
18.
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
J Headache Pain
; 22(1): 152, 2021 Dec 18.
Artigo
Inglês
| MEDLINE | ID: mdl-34922436
19.
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
J Headache Pain
; 22(1): 141, 2021 Nov 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34819017
20.
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Lancet
; 394(10203): 1030-1040, 2019 09 21.
Artigo
Inglês
| MEDLINE | ID: mdl-31427046